Literature DB >> 28584105

Chemical probes to potently and selectively inhibit endocannabinoid cellular reuptake.

Andrea Chicca1, Simon Nicolussi1, Ruben Bartholomäus2, Martina Blunder3,4, Alejandro Aparisi Rey5, Vanessa Petrucci1, Ines Del Carmen Reynoso-Moreno1,6, Juan Manuel Viveros-Paredes6, Marianela Dalghi Gens1, Beat Lutz5, Helgi B Schiöth3, Michael Soeberdt7, Christoph Abels7, Roch-Philippe Charles1, Karl-Heinz Altmann2, Jürg Gertsch8.   

Abstract

The extracellular effects of the endocannabinoids anandamide and 2-arachidonoyl glycerol are terminated by enzymatic hydrolysis after crossing cellular membranes by facilitated diffusion. The lack of potent and selective inhibitors for endocannabinoid transport has prevented the molecular characterization of this process, thus hindering its biochemical investigation and pharmacological exploitation. Here, we report the design, chemical synthesis, and biological profiling of natural product-derived N-substituted 2,4-dodecadienamides as a selective endocannabinoid uptake inhibitor. The highly potent (IC50 = 10 nM) inhibitor N-(3,4-dimethoxyphenyl)ethyl amide (WOBE437) exerted pronounced cannabinoid receptor-dependent anxiolytic, antiinflammatory, and analgesic effects in mice by increasing endocannabinoid levels. A tailored WOBE437-derived diazirine-containing photoaffinity probe (RX-055) irreversibly blocked membrane transport of both endocannabinoids, providing mechanistic insights into this complex process. Moreover, RX-055 exerted site-specific anxiolytic effects on in situ photoactivation in the brain. This study describes suitable inhibitors to target endocannabinoid membrane trafficking and uncovers an alternative endocannabinoid pharmacology.

Entities:  

Keywords:  2-AG; endocannabinoid reuptake; endocannabinoid system; inhibitor; lipid transport

Mesh:

Substances:

Year:  2017        PMID: 28584105      PMCID: PMC5488949          DOI: 10.1073/pnas.1704065114

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  50 in total

Review 1.  Endocannabinoids and Mental Disorders.

Authors:  Tiziana Rubino; Erica Zamberletti; Daniela Parolaro
Journal:  Handb Exp Pharmacol       Date:  2015

Review 2.  Beyond the Direct Activation of Cannabinoid Receptors: New Strategies to Modulate the Endocannabinoid System in CNS-Related Diseases.

Authors:  Andrea Chicca; Chiara Arena; Clementina Manera
Journal:  Recent Pat CNS Drug Discov       Date:  2016

3.  Evidence for bidirectional endocannabinoid transport across cell membranes.

Authors:  Andrea Chicca; Janine Marazzi; Simon Nicolussi; Jürg Gertsch
Journal:  J Biol Chem       Date:  2012-08-09       Impact factor: 5.157

Review 4.  The endocannabinoid system and the brain.

Authors:  Raphael Mechoulam; Linda A Parker
Journal:  Annu Rev Psychol       Date:  2012-07-12       Impact factor: 24.137

5.  Repeated low-dose administration of the monoacylglycerol lipase inhibitor JZL184 retains cannabinoid receptor type 1-mediated antinociceptive and gastroprotective effects.

Authors:  Steven G Kinsey; Laura E Wise; Divya Ramesh; Rehab Abdullah; Dana E Selley; Benjamin F Cravatt; Aron H Lichtman
Journal:  J Pharmacol Exp Ther       Date:  2013-02-14       Impact factor: 4.030

6.  Inhibition of endocannabinoid catabolic enzymes elicits anxiolytic-like effects in the marble burying assay.

Authors:  Steven G Kinsey; Scott T O'Neal; Jonathan Z Long; Benjamin F Cravatt; Aron H Lichtman
Journal:  Pharmacol Biochem Behav       Date:  2010-12-08       Impact factor: 3.533

7.  Cannabinoid receptor 1 is a major mediator of renal fibrosis.

Authors:  Lola Lecru; Christophe Desterke; Stanislas Grassin-Delyle; Christos Chatziantoniou; Sophie Vandermeersch; Aurore Devocelle; Amelia Vernochet; Ninoslav Ivanovski; Catherine Ledent; Sophie Ferlicot; Meriem Dalia; Myriam Saïd; Séverine Beaudreuil; Bernard Charpentier; Aimé Vazquez; Julien Giron-Michel; Bruno Azzarone; Antoine Durrbach; Hélène François
Journal:  Kidney Int       Date:  2015-03-11       Impact factor: 10.612

Review 8.  Peripheral gating of pain signals by endogenous lipid mediators.

Authors:  Daniele Piomelli; Oscar Sasso
Journal:  Nat Neurosci       Date:  2014-01-28       Impact factor: 24.884

9.  One-pot heterogeneous synthesis of Δ(3)-tetrahydrocannabinol analogues and xanthenes showing differential binding to CB(1) and CB(2) receptors.

Authors:  Ornelio Rosati; Federica Messina; Azzurra Pelosi; Massimo Curini; Vanessa Petrucci; Jürg Gertsch; Andrea Chicca
Journal:  Eur J Med Chem       Date:  2014-07-19       Impact factor: 6.514

Review 10.  The endocannabinoid system in guarding against fear, anxiety and stress.

Authors:  Beat Lutz; Giovanni Marsicano; Rafael Maldonado; Cecilia J Hillard
Journal:  Nat Rev Neurosci       Date:  2015-12       Impact factor: 34.870

View more
  24 in total

Review 1.  New approaches and challenges to targeting the endocannabinoid system.

Authors:  Vincenzo Di Marzo
Journal:  Nat Rev Drug Discov       Date:  2018-08-17       Impact factor: 84.694

Review 2.  On the Biomedical Properties of Endocannabinoid Degradation and Reuptake Inhibitors: Pre-clinical and Clinical Evidence.

Authors:  Karen Jaqueline Paredes-Ruiz; Karla Chavira-Ramos; Mario Orozco-Morales; Cimen Karasu; Alexey A Tinkov; Michael Aschner; Abel Santamaría; Ana Laura Colín-González
Journal:  Neurotox Res       Date:  2021-11-06       Impact factor: 3.911

3.  Endocannabinoid Metabolism and Transport as Drug Targets.

Authors:  Francesca Ciaramellano; Federico Fanti; Lucia Scipioni; Mauro Maccarrone; Sergio Oddi
Journal:  Methods Mol Biol       Date:  2023

4.  Novel analogs of PSNCBAM-1 as allosteric modulators of cannabinoid CB1 receptor.

Authors:  Simone Bertini; Andrea Chicca; Francesca Gado; Chiara Arena; Daniela Nieri; Maria Digiacomo; Giuseppe Saccomanni; Pingwei Zhao; Mary E Abood; Marco Macchia; Jürg Gertsch; Clementina Manera
Journal:  Bioorg Med Chem       Date:  2017-10-16       Impact factor: 3.641

5.  Endocannabinoid metabolism and transport as targets to regulate intraocular pressure.

Authors:  Sally Miller; Laura Daily; Vijai Dharla; Juerg Gertsch; Michael S Malamas; Iwao Ojima; Martin Kaczocha; Daisuke Ogasawara; Alex Straiker
Journal:  Exp Eye Res       Date:  2020-09-23       Impact factor: 3.467

Review 6.  Cannabinoid Signaling in the Skin: Therapeutic Potential of the "C(ut)annabinoid" System.

Authors:  Kinga Fanni Tóth; Dorottya Ádám; Tamás Bíró; Attila Oláh
Journal:  Molecules       Date:  2019-03-06       Impact factor: 4.927

7.  The Endocannabinoid Reuptake Inhibitor WOBE437 Is Orally Bioavailable and Exerts Indirect Polypharmacological Effects via Different Endocannabinoid Receptors.

Authors:  Inés Reynoso-Moreno; Andrea Chicca; Mario E Flores-Soto; Juan M Viveros-Paredes; Jürg Gertsch
Journal:  Front Mol Neurosci       Date:  2018-05-28       Impact factor: 5.639

Review 8.  Targeting Cannabinoid Signaling in the Immune System: "High"-ly Exciting Questions, Possibilities, and Challenges.

Authors:  Attila Oláh; Zoltán Szekanecz; Tamás Bíró
Journal:  Front Immunol       Date:  2017-11-10       Impact factor: 7.561

9.  Uncovering the psychoactivity of a cannabinoid from liverworts associated with a legal high.

Authors:  A Chicca; M A Schafroth; I Reynoso-Moreno; R Erni; V Petrucci; E M Carreira; J Gertsch
Journal:  Sci Adv       Date:  2018-10-24       Impact factor: 14.136

Review 10.  The Application of Fluorine-Containing Reagents in Structural Proteomics.

Authors:  Ming Cheng; Chunyang Guo; Michael L Gross
Journal:  Angew Chem Int Ed Engl       Date:  2020-01-16       Impact factor: 15.336

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.